Sumanta Pal: The 1st study to show an OS benefit with ARPI + PARP in mCRPC

Sumanta Pal shared a post on X:

“Woke up to this incredible news from the TALAPRO2 study.

Hugely proud of Neeraj Agarwal, Huntsman Cancer Institute for leading the 1st study to show an OS benefit with ARPI + PARP in mCRPC.

Note PR cites OS benefit in both all comers (cohort 1) and in patients with HRR mutations (cohort 2).

Fascinating and can’t wait to see the data!”

Petros Grivas shared Sumanta Pal’s post on X, and added:

“Agree with Sumanta Pal’s huge news and congrats to Neeraj Agarwal, Huntsman Cancer Institute for leading this important practice impacting trial!

Great news for patients!”

Sumanta (Monty) Pal, MD, is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles.
He serves as the Vice Chair of Academic Affairs, Professor and co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.

Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance.

He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.